Juan Manuel Carreño

10PUBLICATIONS
115CO-AUTHORS
Haematological tumoursPredictive and prognostic markersInnate immunityVeterinary virologyComputational neuroscience (incl. mathematical neuroscience and theoretical neuroscience)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 05, 2025
XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies.

Juan Manuel Carreño, Brian Lerman, Gagandeep Singh

|Jul 27, 2024
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.

Philip C Mack, Chih-Yuan Hsu, Ananda M Rodilla

|Jun 27, 2024
Maturation of germinal center B cells after influenza virus vaccination in humans.

Katherine M McIntire, Hailong Meng, Ting-Hui Lin

|May 15, 2024
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays.

Barbara Mühlemann, Samuel H Wilks, Lauren Baracco

|May 10, 2023
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.

Samuel Ponce-de-León, Martha Torres, Luis Enrique Soto-Ramírez

|Feb 15, 2023
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination.

Juan Manuel Carreño, Ariel Raskin, Gagandeep Singh

Pageof 2

Frequent Collaborators

9 joint publications

Florian Krammer

4 joint publications

Adolfo García-Sastre

3 joint publications

Viviana Simon

2 joint publications

Weina Sun